Workflow
医药行业周报：渤健以超5亿美元囊获Stoke在研ASO疗法Zorevunerse
Tai Ping Yang·2025-02-20 08:30

Investment Rating - The industry investment rating is "Positive," indicating an expected overall return exceeding 5% above the CSI 300 index in the next six months [11]. Core Insights - The pharmaceutical sector showed a performance increase of +0.74% on February 19, 2025, outperforming the CSI 300 index by 0.04 percentage points, ranking 22nd among 31 sub-industries [5]. - Notable sub-industry performances include hospitals (+2.16%), in vitro diagnostics (+1.83%), and medical research outsourcing (+1.43%), while blood products (-0.33%), offline pharmacies (+0.43%), and pharmaceutical distribution (+0.51%) lagged [5]. - A significant collaboration was announced between Bojian and Stoke for the development and commercialization of the ASO therapy Zorevunersen, with Stoke receiving an upfront payment of $165 million and potential milestone payments totaling up to $385 million [6]. Summary by Sections Market Performance - As of February 19, 2025, the pharmaceutical sector's performance was +0.74%, surpassing the CSI 300 index by 0.04 percentage points, with hospitals, in vitro diagnostics, and medical research outsourcing leading the gains [5]. Industry News - Bojian's collaboration with Stoke involves the ASO therapy Zorevunersen, aimed at treating Dravet syndrome, with a total potential financial commitment exceeding $500 million [6]. - Haohai Biological's 2024 revenue is projected at 2.698 billion yuan, a 1.64% increase year-on-year, while net profit is expected to rise by 0.97% to 420 million yuan [6]. - Tonghe Pharmaceutical received market entry approval for its drug in South Korea, enhancing its international market presence [6]. Company News - Prolo Pharmaceutical announced a share buyback plan with a budget of 75 to 150 million yuan, targeting a maximum price of 22 yuan per share [7]. - Newnow's subsidiary reached an agreement with Radiance for the development and commercialization of a drug project, with an initial payment of $15 million and potential milestone payments totaling up to $1.075 billion [7].